1. Inui S. Nalfurafine hydrochloride to treat pruritus: a review. Clin Cosmet Investig Dermatol. 2015 May 11;8:249-55. doi: 10.2147/CCID.S55942.
2. Miyamoto Y, Oh T, Aihara E, Ando A. Clinical Profiles of Nalfurafine Hydrochloride for the Treatment of Pruritus Patients. Handb Exp Pharmacol. 2022;271:455-472. doi: 10.1007/164_2020_400.
3. Ko MJ, Peng YS, Wu HY. Uremic pruritus: pathophysiology, clinical presentation, and treatments. Kidney Res Clin Pract. 2023 Jan;42(1):39-52. doi: 10.23876/j.krcp.21.189.
4. Zhang P, Xiang S, Hu Y, et al. Randomized controlled trial of nalfurafine for refractory pruritus in hemodialysis patients. RENAL FAILURE. 2023. 45;1: 2175590 https://doi.org/ 10.1080/0886022X.2023.2175590.
5. Sumi R, Fukuda K et al. Current status of pruritus in chronic liver diseases and efficacy of nalfurafine hydrochloride. Kanzo, 2017. 58(9), 486–493. Doi: 10.2957/kanzo.58.486
6. Kim J J, Lim J, and Kim Y B. Pathogenesis and Treatment of Pruritus Associated with Chronic Kidney Disease and Cholestasis. Int J Mol Sci. 2023. 24(2):1559. doi: 10.3390/ijms24021559
7. National Center for Advancing Translational Sciences (NCATS). (n.d.). NALFURAFINE HYDROCHLORIDE. Inxight Drugs. 2025. https://drugs.ncats.io/drug/25CC4N0P8J
8. Kumada H, Miyakawa H, Muramatsu T, Ando N, Oh T, Takamori K, Nakamoto H. Efficacy of nalfurafine hydrochloride in patients with chronic liver disease with refractory pruritus: A randomized, double-blind trial. Hepatol Res. 2017. 47(10):972-982. doi: 10.1111/hepr.12830.
9. Kawano T, Atsukawa M, Tsubota A, et al. Shorter pruritus period and milder disease stage are associated with response to nalfurafine hydrochloride in patients with chronic liver disease. Sci Rep, 2022. 12, 7311. https://doi.org/10.1038/s41598-022-11431-1
10. Toray Industries, Inc. Chinese Regulator Approves Toray's REMITCH® Nalfurafine Hydrochloride Orally Disintegrating Tablets for Pruritus Relief. 2023. https://www.toray.com/global/news/details/20230705161619.html
11. Beck TC, Wilson EM, Wilkes E, Lee LW, Norris R, Valdebran M. Kappa opioid agonists in the treatment of itch: just scratching the surface? Itch (Phila). 2023. 8(4):e0072. doi: 10.1097/itx.0000000000000072.
12. European Medicines Agency. Winfuran | European Medicines Agency (EMA). 2014. https://www.ema.europa.eu/ en/medicines/ human/EPAR/winfuran
13. Abishek R, Deevan P. Navigating Drug Approvals: Insights From The USA, Europe, And Japan. International Journal of Pharmaceutical Sciences. 2025. https://www.ijpsjournal.com/article/Navigating+Drug+Approvals+Insights+From+The+USA+Europe+And+Japan
14. BPOM. Product Information dan Assessment Report. Badan POM. 2024. https://registrasiobat.pom.go.id/en/daftar-produk/assesment-report/DKI2456500581A1